Global Single-Cell Genome Sequencing Market by Technology (NGS, PCR, qPCR) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Industry Outlook

In 2016, the global single-cell genome sequencing market was worth USD 730.53 millions. The market is expected to grow at 14.6% during the forecast period. Market growth is being driven by key trends such as increased R&D, an increase in the incidence of severe and chronic immune system disorders, and a growing focus on product development. The market will also benefit from supportive government policies over the forecast period.

The market is being developed thanks to technological advances in single-cell genome sequence technology. Bio-Rad Laboratories, Inc., and Illumina, Inc. have recently collaborated to create an innovative workflow for SCGS analysis. The launch of SCGS was announced by them recently. These technologically advanced platforms provide intuitive analysis software solutions that are cost-effective in nature.

In addition, the market will benefit from supportive government policies during the forecast period. The market will also be driven by a rising number of genomics centres. Many established centers are already working to accelerate advancements through collaboration.

Qiagen, Inc. and Illumina, Inc. are among the many participants in developing and manufacturing NGS-based platforms, tools, and bioinformatics-related sampling and bioinformatics. This is to meet the growing demand for efficient and rapid sequencers. NGS platform allows simultaneous sequencing of multiple targeted genomic areas in different samples in order to detect concomitant mutants simultaneously. This can allow for maximum tumor genomic assessment.

Recent innovations in Drop & Drop Seq were developed by Harvard University researchers. These methods can be used to isolate thousands of cells or prepare sequencing. Academic and commercial researchers are constantly pushing the boundaries of genomics, which is slowly changing the outlook.

Product Insights

In 2016, instruments accounted for the largest share of revenue. The segment's future growth is expected to be driven by the development and implementation of technologically advanced solutions and instruments. The C1 system, for example, allows the preparation of templates to be used in DNA sequencing, mRNA sequence, miRNA expression, and epigenetics. The C1 system can simultaneously isolate, lyse, stain, neutralize, and whole-genome amplification up to 96 cells. It allows for unbiased amplification, which results in genome representations that are more consistent and reproducible. It will continue to dominate the segment until 2025 and expand at the highest rate of CAGR over the forecast period.

Technology Insights

NGS will likely be the fastest-growing technology segment on the market. This segment's growth can be attributed to its extensive R&D activities as well as a wide variety of applications in cancer-related studies. Genome sequencing includes gene isolation, whole-genome construction and sequencing. Combinatorial indexed sequence tools have been developed by researchers that can be used in clinics to guide targeted therapies and noninvasive monitoring.

Microarray also allows for the quantification of thousands genes through hybridization of biological samples to an array that carries thousands synthetic oligonucleotides probles. Microarray technology has been less popular since the advent of NGS technology. Illumina, Inc. is one of the companies that offer advanced microarray systems to support SCG applications.

Multiple displacement amplification (MDA), which is also the most commonly used method for whole-genome amplification prior to SCGS, is another. Multiple studies have shown the feasibility of eWGA using MDA. This simple-to-use method allows researchers to simultaneously detect copy numbers variations (CNVs), single nucleotide Polymorphisms (SNPs), in a single human cell. It significantly improves amplification accuracy as well as uniformity.

Workflow insights

New developments have opened up new avenues for identifying mutation rates, rare cell types, intra-tumor cell heterogeneity, diagnosis and treatment. Multicellular organisms can also be reconstructed using SCG analysis.

Fluidigm is a leader in SCGS-based technologies and techniques. Fluidigm created complex microfluidics systems that were used for single-cell oriented research. Additionally, Illumina, Inc., and 10x Genomics actively participate in the development of advanced genome analysis platforms.

Microfluidic devices are also allowing for the integration of all steps required to sequence samples and generate libraries for up to 96 samples. These systems can reduce DNA input requirements 100 times and improve data handling. The use of fully integrated sample preparation systems based on labon-chip methods can overcome technical barriers and enable greater utilization of genomics in translational and basic investigationsal applications.

Disease Area Insights

In 2016, cancer dominated the single-cell genome sequencing market. The increasing incidence of breast, colorectal and prostate cancers is expected to lead to lucrative growth opportunities. WHO estimates that around 8.8 million people died in 2015 from different types of cancers.

Additionally, growth will be boosted by initiatives from various organizations like the American Cancer Society & Breast Cancer Organization. The American Cancer Society approved funding in excess of USD 39 millions for cancer research and training. This funding will enable technological advances in cancer diagnosis and research.

Application Insights

In 2016, the largest market share was held by circulating cells. The market is growing because of expanding clinical applications of circulating tumour cells (CTCs), which are a biomarker for early detection of cancer. Numerous studies have shown that cell-free DNA is able to accurately represent the tumor genome in both lung cancer and late stage gastric cancer. Cell-free DNA sequenced with tumor origin identifies biomarkers that are associated with the tumor. This helps to determine molecular pathology.

They can also be used to analyze the sequence of mutations and copy in disseminated tumour cells, CTCs, and CTCs. These studies are expected to boost the market's growth over the forecast period. This helps in the diagnosis.

End-use Insights

Research and academic labs will be the largest revenue contributors over the forecast period. This segment is dominated by the growing number of genomic centers and ongoing research in this area. Many genomic centers are involved in the exploration of genome, transcriptome and epigenome single cells to understand disease pathology. The organization also offers high-throughput sequencing and library preparation services.

This field is supported by both the government and private sector. The market will be boosted by the availability of many research facilities, particularly in developed countries. The demand for single-cell genome sequencing is expected to rise in the future due to the increased use of sequencing kits that allow us to study the morphology, function and regulation of many genes under various chronic conditions.

Regional Insights

In 2016, North America was the dominant market, with the U.S. contributing the most revenue. The dominance of this market is due to the increasing incidence of cancer and immunological disorders in the region, as well as technological advances made by entities operating within the region.

The market is expected to grow due to increased research in genomics. For instance, research on microfluidic droplet barcoding at ultra-high-throughput analyzed distributions of phage sequences, antibiotic resistance genes, and virulence factors in microbial communities from an environmental sample. This study was conducted by researchers at the University of California.

Due to increased R&D spending in this field, Asia Pacific will be the fastest growing market segment. The growth of the region market will also be supported by adequate administrative support and collaborations between entities from Asian countries.

Multiple displacement amplification is being studied for genome amplification. Researchers at Waseda University claim that this method can be used to amplify the whole genome of cancer cells as well as single bacteria cells. These activities will increase the market's growth over the forecast period.

Single Cell Genome Sequencing Market share Insights

Bio-Rad Laboratories, 10x Genomics, Novogene, Fluidigm, BGI; Illumina, Inc., Oxford Nanopore Technologies, Pacific Biosciences, Thermo Fisher Scientific, Inc., QIAGEN, and F Hoffmann-La Roche Ltd. are the major players in this market.

Key market players are currently forming partnerships to expand their product ranges. To expand their business and maintain a competitive edge, companies are expanding their R&D, distribution and management capabilities.

Illumina, Inc. and Bio-Rad jointly launched a single-cell genome sequencing solution in January 2017. Researchers will be able to use this launch to study the roles of individual cells in disease progressions, therapeutic responses, and tissue function. In February 2016, Qiagen also announced its partnership with 10x Genomics, Inc. To develop integrated workflow solutions, the two entities signed a co-marketing agreement and a co-development agreement.

The Report Covers Certain Segments

This report predicts revenue growth at the global, regional and country level and offers analysis on industry trends and opportunities for each sub-segment from 2014 through 2025. Grand View Research has divided the global single-cell genomic sequencing market report based on product, technology, workflow and disease area. The end uses are also included.

• Product Outlook (Revenue USD Million, 2014-2025)

  • Instruments

  • Reagents

• Technology Outlook (Revenue USD Million, 2014-2025)

  • NGS

  • PCR

  • qPCR

  • Microarray

  • MDA

• Workflow Outlook (Revenue USD Million, 2014-2025)

  • Isolation

  • Sample preparation

  • Genomic analysis

• Disease Area Outlook (Revenue USD Millions, 2014-2025)

  • Cancer

  • Immunology

  • Prenatal diagnosis

  • Neurobiology

  • Microbiology

  • Other

• App Outlook (Revenue USD Million, 2014-2025)

  • CTCs

  • Differentiation/ Reprogramming

  • Genomic variation

  • Characterization of subpopulations

  • Other

• End-use Outlook (Revenue USD Million, 2014-2025)

  • Academic & Research Laboratories

  • Companies in biotechnology and biopharmaceutical

  • Clinics

  • Other

• Regional Outlook (Revenue USD Million, 2014-2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • The U.K.

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

  • Middle East and Africa (MEA).

    • South Africa

Up Market Research published a new report titled “Single-Cell Genome Sequencing Market research report which is segmented by Technology (NGS, PCR, qPCR), By Players/Companies Inc; Oxford Nanopore Technologies; Pacific Biosciences; Thermo Fisher Scientific, Inc; QIAGEN; and F Hoffmann-La Roche Ltd, Bio-Rad Laboratories; 10x Genomics; Novogene; Fluidigm; BGI; Illumina”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Single-Cell Genome Sequencing Market Report Segments:

The market is segmented by Technology (NGS, PCR, qPCR).

Single-Cell Genome Sequencing Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Single-Cell Genome Sequencing Market

Overview of the regional outlook of the Single-Cell Genome Sequencing Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Single-Cell Genome Sequencing Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Single-Cell Genome Sequencing Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. NGS

                2. PCR

                3. qPCR

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Single-Cell Genome Sequencing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Single-Cell Genome Sequencing Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.